Get the Stockscreener App
12.97
0.61%
-0.08
After Hours:
12.99
0.02
+0.15%
Immunic Inc stock is traded at $12.97, with a volume of 247.88K.
It is down -0.61% in the last 24 hours and up +47.37% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
See More
Previous Close:
$13.05
Open:
$13.25
24h Volume:
247.88K
Relative Volume:
0.85
Market Cap:
$176.67M
Revenue:
-
Net Income/Loss:
$-97.17M
P/E Ratio:
-1.7374
EPS:
-7.465
Net Cash Flow:
$-85.97M
1W Performance:
+11.81%
1M Performance:
+47.37%
6M Performance:
+85.02%
1Y Performance:
+41.35%
1-Day Range:
$12.65
$13.70
1-Week Range:
$10.87
$13.80
52-Week Range:
$5.062
$15.10
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
12.97 | 177.76M | 0 | -97.17M | -85.97M | -7.465 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-15-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Nov-07-25 | Initiated | Roth Capital | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Wolfe Research initiated coverage on Immunic - Quantisnow
IMUX Maintained by B. Riley Securities -- Price Target Lowered t - GuruFocus
Immunic (IMUX) Price Target Reduced by B. Riley Analyst - GuruFocus
B. Riley Securities Maintains Immunic(IMUX.US) With Buy Rating, Cuts Target Price to $27 - Moomoo
B. Riley Adjusts Price Target on Immunic to $27 From $40, Maintains Buy Rating - Moomoo
Wolfe Research initiates Immunic stock with outperform rating - Investing.com
Wolfe Research initiates Immunic stock with outperform rating By Investing.com - Investing.com Canada
Immunic Appoints New Chair of Board - Intellectia AI
IMMUNIC (IMUX) director Michael W. Bonney listed as insider in Form 3 filing - Stock Titan
Immunic Appoints Michael W. Bonney as Board Chair to Guide Late-Stage MS Therapy Development and Commercialization - Minichart
Immunic names Michael Bonney as board chair By Investing.com - Investing.com South Africa
Immunic appoints Michael Bonney as chairman - The Pharma Letter
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - Yahoo Finance
Immunic Appoints New Chair of Board of Directors - Intellectia AI
Immunic Appoints Michael Bonney as Board Chair - TipRanks
Immunic Names Michael Bonney as Board Chair - Moomoo
Biotech veteran Michael Bonney becomes Immunic (NASDAQ: IMUX) chair - Stock Titan
Immunic names Michael Bonney as board chair - Investing.com
Immunic appoints seasoned biopharmaceutical executive Michael W. Bonney as chair of the board of directors - marketscreener.com
Press Release: Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors - Moomoo
Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Immunic stock (US45256V1061): Q1 loss widens as short interest collapses - AD HOC NEWS
Alyeska discloses 6.33M-share stake in Immunic (NASDAQ: IMUX) - Stock Titan
Immunic, Inc.Common Stock (NQ: IMUX - FinancialContent
Immunic announces 1-for-10 reverse stock split - MSN
A Quick Look at Today's Ratings for Immunic(IMUX.US), With a Forecast Between $19 to $56 - Moomoo
IMMUNIC (IMUX) amendment shows 683 Capital exit filing and 3.4% beneficial stake - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Immunic (IMUX), Tenon Medical, Inc. (TNON) - The Globe and Mail
Number of shareholders of Immunic, Inc. – NASDAQ:IMUX - TradingView
Roth MKM Maintains Immunic(IMUX.US) With Buy Rating, Cuts Target Price to $19 - Moomoo
Number of shareholders of Immunic, Inc. – FWB:10V - TradingView
H.C. Wainwright reiterates Immunic stock rating citing trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Immunic stock rating citing trial progress - Investing.com UK
Immunic stock (US45256V1061): Q1 earnings and Phase 3 trial preparations - AD HOC NEWS
Immunic (IMUX) Q1 2026 Earnings: EPS N/A, Revenue N/A -- Is the - GuruFocus
Immunic Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Immunic (IMUX) Prepares for Pivotal Phase 3 Trials with Strength - GuruFocus
Immunic Releases Q1 2026 Financial Results - AlphaStreet
Immunic, Inc. Reports Q1 2026 Financial Results, Advances Phase 3 Trials for Vidofludimus Calcium in Multiple Sclerosis, and Raises $200M in Private Placement - Minichart
Immunic advances Phase 3 MS program, eyes topline data by year-end - Yahoo Finance
Immunic CEO on Q1 highlights, new appointments and upcoming milestones - Proactive financial news
Immunic, Inc. Q1 2026 Financial Results and Clinical Progress in Neurologic Disease Therapies - Minichart
IMUX: Vidofludimus calcium shows strong efficacy and safety in MS, targeting a $3-7B market - TradingView
Immunic reports Q1 2026 net loss $32.6M, cash $186.6M after $200M private placement - TradingView
IMMUNIC ($IMUX) Releases Q1 2026 Earnings - Quiver Quantitative
IMMUNIC, INC. 1Q 2026: Revenue $0 Net loss $32.6M — 10-Q Summary - TradingView
Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Immunic (NASDAQ: IMUX) boosts cash with $200M warrant deal amid Q1 loss - Stock Titan
Immunic: Q1 Earnings Snapshot - marketscreener.com
Press Release: Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunic Inc Stock (IMUX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
| Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
| Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
| Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
| Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
| Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):